RDH: A Promising Drug Target Or Biomarker for Retinol Metabolism
RDH: A Promising Drug Target Or Biomarker for Retinol Metabolism
Retinol dehydrogenase (RDH) is an enzyme involved in the metabolism of retinol, a form of vitamin A that is essential for vision and skin health. RDH is a nonspecific subtype of the enzyme retinol dehydrogenase (RDH), which is a key enzyme in the retinol cycle, a process that is responsible for the production and breakdown of retinol in the body. In this article, we will discuss the research on RDH and its potential as a drug target or biomarker.
The retinol cycle is a critical process for maintaining good vision and skin health. It is a complex series of steps that involve the breakdown and formation of retinol, which is a form of vitamin A. The first step in the retinol cycle is the 25-carboxylic acid (25-carboxy) phase, which is catalyzed by RDH. In this phase, RDH converts 25-carboxy retinol to 25-carboxyretinol. This conversion is critical for the production of retinol, which is then broken down into its active form, retinol, by the enzyme retinol dehydrogenase (RDH).
RDH is a family of enzymes that are involved in the metabolism of a wide range of compounds, including drugs, toxins, and other substances that are harmful to the body. The RDH enzyme has been identified as a potential drug target or biomarker due to its involvement in the production and breakdown of retinol.
One of the key advantages of RDH as a drug target is its expression in various tissues and cells throughout the body. RDH is highly expressed in the liver, kidneys, and retina, making it an attractive target for drugs that are designed to modulate its activity. Additionally, the fact that RDH is a nonspecific subtype of the enzyme retinol dehydrogenase (RDH) makes it more accessible to drugs that target other subtypes of RDH, such as the alpha subtype.
Another advantage of RDH is its involvement in the production of retinol, which is a critical macronutrient for the body. Retinol is involved in a wide range of physiological processes in the body, including the development and maintenance of hair, skin, and nails, as well as the regulation of cell growth and differentiation. Additionally, retinol is also involved in the production of other compounds that are important for vision and eye health, such as visual acuity and the macular pigment.
In addition to its role in the production and breakdown of retinol, RDH is also involved in the regulation of other compounds that are important for cellular health and function. For example, RDH is involved in the production of the molecule dihydroretin, which is a key component of the retina and plays a role in the regulation of visual function. Additionally, RDH is also involved in the production of the molecule retinal, which is a key component of the retina and is involved in the regulation of vision.
Overall, RDH is a promising drug target or biomarker due to its involvement in the production and breakdown of retinol. The fact that it is a nonspecific subtype of the enzyme retinol dehydrogenase (RDH) makes it more accessible to drugs that target other subtypes of RDH, as well as its involvement in the production and regulation of other compounds that are important for cellular health and function. Further research is needed to fully understand the potential of RDH as a drug target or biomarker.
Protein Name: Retinol Dehydrogenase (nonspecified Subtype)
The "Retinol dehydrogenase Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Retinol dehydrogenase comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
RETN | RETNLB | RETREG1 | RETREG2 | RETREG3 | RETSAT | REV1 | REV3L | Reverse transcriptase (Telomerase) | REX1BD | REXO1 | REXO1L1P | REXO1L2P | REXO1L6P | REXO1L8P | REXO2 | REXO4 | REXO5 | RFC1 | RFC2 | RFC3 | RFC4 | RFC5 | RFESD | RFESDP1 | RFFL | RFK | RFLNA | RFLNB | RFNG | RFPL1 | RFPL1S | RFPL2 | RFPL3 | RFPL3S | RFPL4A | RFPL4AL1 | RFPL4B | RFT1 | RFTN1 | RFTN2 | RFWD3 | RFX complex | RFX1 | RFX2 | RFX3 | RFX3-DT | RFX4 | RFX5 | RFX5-AS1 | RFX6 | RFX7 | RFX8 | RFXANK | RFXAP | RGCC | RGL1 | RGL2 | RGL3 | RGL4 | RGMA | RGMB | RGMB-AS1 | RGN | RGP1 | RGPD1 | RGPD2 | RGPD3 | RGPD4 | RGPD4-AS1 | RGPD5 | RGPD6 | RGPD8 | RGR | RGS1 | RGS10 | RGS11 | RGS12 | RGS13 | RGS14 | RGS16 | RGS17 | RGS18 | RGS19 | RGS2 | RGS20 | RGS21 | RGS22 | RGS3 | RGS4 | RGS5 | RGS6 | RGS7 | RGS7BP | RGS8 | RGS9 | RGS9BP | RGSL1 | RHAG | RHBDD1
